U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07133178) titled 'A Phase 3 Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children Aged 1 to 11 Years.' on Aug. 13.
Brief Summary: VLA1553-322 is a multicenter, prospective, randomized, double-blind, phase 3 clinical trial evaluating VLA1553 in comparison to a comparator (Nimenrix(R)) for each stratum (age group). At least 3,000 male and female healthy children aged 1 to 11 years will be enrolled and randomized 3:1 to either VLA1553 (n=2,250) or comparator (Nimenrix(R)) (n=750).
Study Start Date: Feb. 06, 2026
Study Type: INTERVENTIONAL
Condition:
Chikungunya Virus Infection
Intervention:
BIOLOGICAL: VLA1553
Single intr...